Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 39 Women only

Reversible Effects of Stopping Oral Contraceptives on Brain Serotonin Receptors

Official title: Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission

Run by Copenhagen University Hospital, Rigshospitalet · NCT07511439 · Data updated 2026-11-12

This study tests whether stopping a common birth control pill increases brain serotonin 4 receptor binding in healthy adult women who have been using a second-generation pill.

More Healthy Adult Females trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 39 Years
SexWomen only
Enrollment60 (estimated)
SponsorCopenhagen University Hospital, Rigshospitalet
Academic / other
Drugs / interventionsradiation
Locations1 site (Copenhagen)
StatusRecruiting
StartedApril 23, 2026
Main results expectedDecember 31, 2030
Study endsDecember 31, 2030
Registry record updatedJuly 2, 2026
Trial IDNCT07511439 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy women aged 18-39 who have used a second-generation COC (150 µg levonorgestrel and 30 µg ethinylestradiol) for at least 3 months.

Probably not a fit

People with current or past neurological/psychiatric disorders or those unable to comply with study procedures may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will randomly assign healthy women aged 18-39 who currently use a specific combined oral contraceptive to discontinue or continue use for up to one year. Brain imaging with PET will measure 5-HT4 receptor binding at baseline and after follow-up to see if stopping the pill restores receptor levels toward those seen in non-users. The study also explores how changes relate to mood, memory, and sexual desire, with the goal of understanding whether any COC-related brain changes are reversible. Up to 60 participants will be enrolled at Copenhagen University Hospital, Rigshospitalet, with careful screening for MRI safety and other eligibility factors.

Why it matters

Potential benefit: If successful, the study could clarify whether COC-related brain changes are reversible and inform strategies for managing mood-related side effects.

How similar studies have gone: Previous work suggests COC use reduces 5-HT4 receptor levels, and disrupting use may allow recovery, supporting a plausible effect in this study.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Healthy women (assigned female at birth) at 18-39 years of age
2. Currently using a second-generation combined oral contraceptive containing 150 ug levonorgestrel and 30 ug ethinylestradiol for at least 3 months

Exclusion Criteria:

1. Current or previous neurological or psychiatric disease, severe somatic disease, or consumption of medical drugs (including psychoactive medication) likely to influence the test results
2. Non-fluent in Danish or pronounced visual or auditory impairments
3. Current or past learning disability
4. Pregnancy within the last year or previous pregnancy lasting into second or third trimester
5. A wish to become pregnant within the following 12 months
6. Participation in experiments with exposure to radioactivity (\> 10 mSv) within the last year or significant occupational exposure to radioactivity
7. Contraindications for MRI (pacemaker, metal implants, claustrophobia)
8. A history of head injury or concussion resulting in loss of consciousness for more than 2 min
9. Alcohol or drug abuse
10. Drug use other than tobacco and alcohol within the last 30 days
11. Cannabis \> 50 x lifetime
12. Recreational drugs other than cannabis \> 10 x lifetime (for each substance)
13. Nicotine addiction
14. Non-compliance to COC within the last 3 months (i.e., \> 2 missed pills in a cycle)
15. Contraindication for use of combined oral contraception

Where it's running

  • Neurobiology Research Unit (NRU)
    Copenhagen, Denmark
    Recruiting

Study contacts

  • Principal investigator: Søren Vinther Larsen, MD, PhD — Neurobiology Research Unit, Rigshospitalet
  • Study coordinator: Søren Vinther Larsen, MD, PhD
  • Email: soren.vinther@nru.dk
  • Phone: +45 35456708

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.